In 2020, Pluristem Therapeutics’ PLX-PAD Will Earn Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Peripheral Arterial DiseaseLast update: 3/21/2012 9:00:01

AMPLX-PAD Will Displace the Current Proprietary Clinical Gold Standard for the Indication, Ramipril, According to Findings from Decision Resources

BURLINGTON, Mass., Mar 21, 2012 (BUSINESS WIRE) -- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, Pluristem Therapeutics’ PLX-PAD will earn Decision Resources’ proprietary clinical gold standard status for the treatment of peripheral arterial disease (intermittent claudication) in 2020. Owing to its competitive advantages in efficacy, PLX-PAD (which will launch for the indication in 2016), will displace Decision Resources’ current proprietary clinical gold standard for peripheral arterial disease, ramipril (Pfizer’s Altace/Sanofi’s Triatec, generics).

The DecisionBase 2012 report entitled Peripheral Arterial Disease: Surveyed Cardiologists See Commercial Potential for Cell-Based Therapies Ixmyelocel-T and PLX-PAD, finds that surveyed U.S. cardiologists and managed care organization (MCO) pharmacy directors agree that effect on walking performance is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in peripheral arterial disease (intermittent claudication). Clinical data and the opinions of interviewed thought leaders indicate that Aastrom Biosciences’ ixmyelocel-T and PLX-PAD have advantages over cilostazol (Otsuka’s Pletaal/Pletal, generics) on this attribute.

According to insights from surveyed U.S. cardiologists and MCO pharmacy directors, drugs that elicit greater reductions in the risk of mortality is one of the greatest unmet needs in peripheral arterial disease (intermittent claudication).

“However, according to clinical data and the opinions of thought leaders we interviewed, none of the emerging therapies covered in our report have demonstrated the potential to fulfill this unmet need,” said Decision Resources Analyst Christine Helliwell, Ph.D.